Q-omics provides the consensus-scored ANKS1A profile across patient tissues and cancer cell-line models. ANKS1A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANKS1A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ANKS1A RNA expression shows 19,993 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where ANKS1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKS1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKS1A survival associations across molecular data types. ANKS1A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKS1A RNA expression–survival associations across cancer types. High ANKS1A expression shows unfavorable associations in LIHC, but favorable associations in HNSC, KIRC, READ, SCLC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for ANKS1A RNA expression.
This table summarizes ANKS1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKS1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKS1A shows lower tumor expression in THCA, LUAD, LUSC and BRCA and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher ANKS1A RNA expression in tumor versus normal tissue (log2 FC = +0.834, t-test p < 0.001).
This table shows molecular features associated with ANKS1A in patient tissues and cancer cell lines. In patient samples, ANKS1A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKS1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
